Gambaran Umum
Biofrontera Inc. is a biopharmaceutical company based in the United States, primarily engaged in the development and commercialization of dermatological products and therapies. Its core focus is on the treatment and management of skin conditions, primarily actinic keratosis, a type of precancerous skin lesion caused by sun exposure. A key product of Biofrontera is Ameluz®, a prescription medication used in combination with the company’s photodynamic therapy lamp, BF-RhodoLED®, for treating mild and moderate actinic keratosis on the face and scalp. The company is involved in continuous research to expand the indications for its products and improve therapeutic outcomes in dermatological care, positioning itself as a leader in photodynamic therapy innovations.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai revenue untuk Biofrontera Inc. per 2025 Jun 30 adalah 39.19 MM.
- Nilai operating income untuk Biofrontera Inc. per 2025 Jun 30 adalah -16.30 MM.
- Nilai net income untuk Biofrontera Inc. per 2025 Jun 30 adalah -16.59 MM.
| Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
| 2025-06-30 | 39.19 | -16.30 | -16.59 |
| 2025-03-31 | 38.00 | -16.29 | -11.53 |
| 2024-12-31 | 37.32 | -17.21 | -17.76 |
| 2024-09-30 | 35.36 | -19.36 | -12.84 |
| 2024-06-30 | 35.24 | -18.82 | -13.51 |
| 2024-03-31 | 33.25 | -22.25 | -23.09 |
| 2023-12-31 | 34.07 | -21.35 | -20.13 |
| 2023-09-30 | 33.62 | -21.94 | -26.44 |
| 2023-06-30 | 29.05 | -23.67 | -22.67 |
| 2023-03-31 | 27.66 | -22.98 | -13.68 |
| 2022-12-31 | 28.67 | -21.51 | -0.64 |
| 2022-09-30 | 27.70 | -10.69 | -12.36 |
| 2022-06-30 | 27.71 | -19.76 | -25.81 |
| 2022-03-31 | 29.11 | -14.96 | -28.62 |
| 2021-12-31 | 24.10 | -14.60 | -37.71 |
| 2021-09-30 | 23.50 | -20.98 | -23.39 |
| 2021-06-30 | 22.42 | -7.83 | -10.37 |
| 2021-03-31 | 18.97 | -7.34 | -10.42 |
| 2020-12-31 | 18.85 | -8.33 | -10.99 |
Laporan Laba Rugi: EPS
| Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
| 2025-06-30 | ||
| 2025-03-31 | ||
| 2024-12-31 | -3.22 | -3.22 |
| 2024-09-30 | -3.08 | -3.08 |
| 2024-06-30 | -4.44 | -4.44 |
| 2024-03-31 | -10.90 | -10.90 |
| 2023-12-31 | -13.02 | |
| 2023-09-30 | -19.83 | -19.84 |
| 2023-06-30 | -17.60 | -17.60 |
| 2023-03-31 | -11.62 | -11.56 |
| 2022-12-31 | -0.61 | |
| 2022-09-30 | -14.14 | -14.15 |
| 2022-06-30 | -37.42 | -37.42 |
| 2022-03-31 | -51.64 | -51.80 |
| 2021-12-31 | -85.63 | -85.63 |
| 2021-09-30 | -58.48 | -58.46 |
| 2021-06-30 | -25.92 | -25.93 |
| 2021-03-31 | -26.04 | -26.01 |
| 2020-12-31 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Biofrontera Inc. per 2025 Jun 30 adalah -9.39 MM.
- Nilai cash from investing activities untuk Biofrontera Inc. per 2025 Jun 30 adalah -0.01 MM.
- Nilai kas dari aktivitas pendanaan untuk Biofrontera Inc. per 2025 Jun 30 adalah 12.25 MM.
| Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
| 2025-06-30 | -9.39 | -0.01 | 12.25 |
| 2025-03-31 | -11.06 | -0.01 | 9.04 |
| 2024-12-31 | -10.27 | -0.00 | 14.84 |
| 2024-09-30 | -18.12 | 0.07 | 17.50 |
| 2024-06-30 | -18.91 | 0.45 | 18.39 |
| 2024-03-31 | -24.53 | 0.63 | 14.21 |
| 2023-12-31 | -24.89 | 0.62 | 8.41 |
| 2023-09-30 | -24.30 | -1.54 | 1.70 |
| 2023-06-30 | -28.24 | -4.96 | 5.74 |
| 2023-03-31 | -17.78 | -5.17 | 14.02 |
| 2022-12-31 | -16.20 | -5.16 | 14.02 |
| 2022-09-30 | -28.92 | -3.08 | 57.85 |
| 2022-06-30 | -24.19 | -0.04 | 53.10 |
| 2022-03-31 | -25.38 | -0.02 | 43.19 |
| 2021-12-31 | -26.71 | -0.01 | 43.19 |
| 2021-09-30 | -6.39 | -0.00 | 3.70 |
| 2021-06-30 | -6.02 | -0.00 | 4.63 |
| 2021-03-31 | -9.19 | 11.89 | |
| 2020-12-31 | -12.37 | 13.19 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
| Period End (TTM) | p/e | P/Book | P/TBV |
| 2025-06-30 | |||
| 2025-03-31 | |||
| 2024-12-31 | |||
| 2024-09-30 | |||
| 2024-06-30 | |||
| 2024-03-31 | |||
| 2023-12-31 | |||
| 2023-09-30 | |||
| 2023-06-30 | |||
| 2023-03-31 | |||
| 2022-12-31 | |||
| 2022-09-30 | |||
| 2022-06-30 | |||
| 2022-03-31 | |||
| 2021-12-31 | |||
| 2021-09-30 | |||
| 2021-06-30 | |||
| 2021-03-31 | |||
| 2020-12-31 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
| Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
| 2025-06-30 | ||
| 2025-03-31 | ||
| 2024-12-31 | ||
| 2024-09-30 | ||
| 2024-06-30 | ||
| 2024-03-31 | ||
| 2023-12-31 | ||
| 2023-09-30 | ||
| 2023-06-30 | ||
| 2023-03-31 | ||
| 2022-12-31 | ||
| 2022-09-30 | ||
| 2022-06-30 | ||
| 2022-03-31 | ||
| 2021-12-31 | ||
| 2021-09-30 | ||
| 2021-06-30 | ||
| 2021-03-31 | ||
| 2020-12-31 |
Efektivitas Manajemen
- roa untuk Biofrontera Inc. pada 2025 Jun 30 adalah -0.53.
- roe untuk Biofrontera Inc. pada 2025 Jun 30 adalah -1.52.
- roic untuk Biofrontera Inc. pada 2025 Jun 30 adalah -2.16.
- croic untuk Biofrontera Inc. pada 2025 Jun 30 adalah -0.38.
- ocroic untuk Biofrontera Inc. pada 2025 Jun 30 adalah -2.07.
| Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
| 2025-06-30 | -0.53 | -1.52 | -2.16 | -0.38 | -2.07 |
| 2025-03-31 | -0.72 | -1.90 | 0.49 | -1.10 | |
| 2024-12-31 | -0.46 | -3.71 | -1.88 | -0.08 | -2.66 |
| 2024-09-30 | -0.38 | -12.37 | -1.09 | -0.01 | -1.53 |
| 2024-06-30 | -0.55 | -1.38 | -12.69 | -5.32 | -13.48 |
| 2024-03-31 | -0.40 | -0.84 | -1.98 | -1.56 | -2.44 |
| 2023-12-31 | -0.48 | -1.17 | -6.86 | -6.27 | -6.31 |
| 2023-09-30 | -0.42 | -1.32 | -2.42 | -2.93 | -3.01 |
| 2023-06-30 | -0.42 | -1.32 | -2.42 | -2.93 | -3.01 |
| 2023-03-31 | -0.28 | -0.79 | -0.76 | -0.50 | -0.99 |
| 2022-12-31 | -0.81 | -0.55 | 1.14 | -1.28 | |
| 2022-09-30 | -0.81 | -0.55 | 1.14 | -1.28 | |
| 2022-06-30 | -1.46 | -1.50 | 1.67 | -1.40 | |
| 2022-03-31 | -1.38 | -12.48 | -1.64 | 1.02 | -1.46 |
| 2021-12-31 | -1.56 | -6.47 | -3.33 | 1.45 | -2.36 |
| 2021-09-30 | |||||
| 2021-06-30 | -0.36 | ||||
| 2021-03-31 | -0.36 | -4.54 | 1.18 | -4.01 | |
| 2020-12-31 | -0.38 | -1.89 | 0.14 | -2.12 |
Gross Margins
- marjin kotor untuk Biofrontera Inc. pada 2025 Jun 30 adalah 0.53.
- marjin bersih untuk Biofrontera Inc. pada 2025 Jun 30 adalah -0.30.
- marjin operasi untuk Biofrontera Inc. pada 2025 Jun 30 adalah -0.43.
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
| Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
| 2025-06-30 | 0.53 | -0.30 | -0.43 |
| 2025-03-31 | 0.50 | -0.48 | -0.46 |
| 2024-12-31 | 0.47 | -0.36 | -0.51 |
| 2024-09-30 | 0.48 | -0.38 | -0.50 |
| 2024-06-30 | 0.49 | -0.69 | -0.67 |
| 2024-03-31 | 0.49 | -0.59 | -0.63 |
| 2023-12-31 | 0.48 | -0.79 | -0.65 |
| 2023-09-30 | 0.48 | -0.78 | -0.77 |
| 2023-06-30 | 0.48 | -0.78 | -0.77 |
| 2023-03-31 | 0.47 | -0.49 | -0.83 |
| 2022-12-31 | 0.47 | -0.45 | -0.39 |
| 2022-09-30 | 0.47 | -0.45 | -0.39 |
| 2022-06-30 | 0.47 | -0.93 | -0.72 |
| 2022-03-31 | 0.47 | -0.98 | -0.51 |
| 2021-12-31 | 0.47 | -1.56 | -0.61 |
| 2021-09-30 | 0.47 | -1.00 | -0.41 |
| 2021-06-30 | 0.50 | -0.46 | -0.35 |
| 2021-03-31 | 0.51 | -0.55 | -0.39 |
| 2020-12-31 | 0.52 | -0.58 | -0.44 |
Pengenal dan Deskriptor
| Kunci Indeks Pusat (CIK) | 1858685 |
Grupong Pang-industriya
| SIC 2834 - Pharmaceutical Preparations |
